---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-102394"
form_type: "8-K"
ticker: "ITRMF"
cik: "0001659323"
company_name: "Iterum Therapeutics plc"
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:46:57.002132+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Iterum reports Q2 net loss $6.5M; ORLYNVAH launch on track for August 2025

## Summary
- Net loss $6.5M (non-GAAP $5.1M) vs $5.0M prior year; cash $13.0M at June 30, 2025.
- ORLYNVAH™ launch expected by end of August 2025 for uUTIs; first oral penem approved in U.S.
- Entered commercialization agreement with EVERSANA; hired Christine Coyne as CCO.
- Pfizer extended $20M milestone payment deferral to October 2029.
- Canadian patent issued covering sulopenem/probenecid combination, expiring 2039.

## SEC filing metadata
- accession: 0000950170-25-102394
- form_type: 8-K
- ticker: ITRMF
- cik: 0001659323
- company_name: Iterum Therapeutics plc
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659323/000095017025102394/0000950170-25-102394-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659323/000095017025102394/itrm-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-102394
- JSON: https://secwatch.observer/filing/0000950170-25-102394.json
- Plain text: https://secwatch.observer/filing/0000950170-25-102394.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.